Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interleukin-15 × Dermatologic × Clear all
NCT01369888 2015-01-27

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 8 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡